Resistant hypertension causes significant organ damage, and higher aldosterone and cortisol levels have been implicated in its pathophysiology. In the pre-clinical and the phase 1 trial, the drug baxdrostat had shown promising results in reducing plasma aldosterone levels. Recently, a multicenter, placebo-controlled phase 2 trial has reported the efficacy of baxdrostat in managing treatment-resistant hypertension.
This trial has established that baxdrostat can achieve dose-related reductions in blood pressure without significant adverse events (including adrenocortical insufficiency) in cases of treatment-resistant hypertension. Is baxdrostat a potential cure for treatment-resistant hypertension?
